Whalesbook
The United States faces a significant, yet potentially overlooked, vulnerability in its pharmaceutical supply chain: China's dominant control over the raw materials needed to manufacture essential medicines.
Geopolitical Leverage in Pharmaceuticals
- While trade tensions with China persist, Beijing holds a powerful lever through its near-monopoly on the foundational ingredients for many global drugs.
- This issue is central to the US-China Economic and Security Review Commission's annual report, which urges Congress to amend a 2020 law.
- The proposed amendment would grant the Federal Food and Drug Administration (FDA) greater authority to demand pharmaceutical companies report the volume and origin of drug building blocks.
China's Dominance in Drug Production
- The US and other nations heavily rely on China for producing Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs), the core components of modern drugs.
- China's massive, commoditized industry, established since the 1950s, gives it an outsized role in the global drug supply chain.
Alarming Dependence Revealed
- Data from the US Pharmacopeia, a nonprofit setting medicine quality standards, shows a dramatic shift.
- In 1980, China was not a significant player in FDA filings for drug master files.
- By 2000, it accounted for 5% of filings, while India led at 19%.
- Last year, China surpassed India with a 45% share of total filings.
- The situation is further complicated as India, a top generic drug supplier, itself depends heavily on China for KSMs.
- Alarmingly, half of the active ingredients used in the US originate from a single source, with China being the exclusive supplier for at least one chemical used in nearly 700 critical medicines.
Risks and Future Expectations
- The COVID-19 pandemic highlighted the dangers of over-reliance on single sources for critical supplies.
- Leland Miller, a member of the US security review commission, described Beijing's control over active drug ingredients as a "scary chunk."
- The goal is to build a supply chain independent of China, potentially involving allies like India.
- However, replicating China's low-cost production of KSMs would likely increase costs by as much as 50% for US firms.
- Washington may need to explore models similar to the Pentagon's agreement with rare earths producer MP Materials Corp., which includes a price floor to ensure domestic supply.
Impact
- This situation poses a significant risk to global public health and national security by creating potential supply chain chokepoints.
- Drug availability and prices could be affected by geopolitical actions or future disruptions.
- The US and its allies face the challenge of diversifying their pharmaceutical ingredient sources to mitigate these risks.
- Impact Rating: 8/10
Difficult Terms Explained
- Key Starting Materials (KSMs): The basic chemical compounds used as the initial ingredients in the complex process of manufacturing pharmaceutical ingredients.
- Active Pharmaceutical Ingredients (APIs): The biologically active component of a drug that produces the intended therapeutic effect.
- US-China Economic and Security Review Commission: A U.S. congressional commission established to monitor, review, and report on the national security implications of the U.S. economic relationship with China.
- Federal Food and Drug Administration (FDA): A U.S. government agency responsible for protecting public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products, medical devices, our nation's food supply, cosmetics, and products that emit radiation.
- Generic Medicines: Medications that are equivalent to a brand-name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use.
- Supply Chain Chokepoint: A point in a supply chain where the flow of goods or services is critically constrained, making it vulnerable to disruption.